Testing effectiveness (Phase 2)Looking for participantsNCT05536505What this trial is testingAdjuvant Treatment Based on MRD for EGFR Mutant NSCLCWho this might be right forMRD Guangdong Association of Clinical Trials 180
Testing effectiveness (Phase 2)Looking for participantsNCT05011487What this trial is testingNeoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLCWho this might be right forNon-Small Cell Lung Cancer Sun Yat-sen University 30
Early research (Phase 1)Study completedNCT02364609What this trial is testingPembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to ErlotinibWho this might be right forRecurrent Non-Small Cell Lung CarcinomaStage IIIA Non-Small Cell Lung CancerStage IIIB Non-Small Cell Lung Cancer+1 more Jonathan Riess 11
Testing effectiveness (Phase 2)Looking for participantsNCT04486833What this trial is testingQuaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on OsimertinibWho this might be right forCarcinoma, Non-Small Cell Lung Genprex, Inc. 158
Not applicableLooking for participantsNCT04324164What this trial is testingSurvival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLCWho this might be right forNon-small Cell Lung Cancer Hunan Province Tumor Hospital 800
Large-scale testing (Phase 3)Looking for participantsNCT07738172What this trial is testingOsimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung CancerWho this might be right forLung Neoplasms, Non-Small Cell Lung Cancer National Taiwan University Hospital 154
Testing effectiveness (Phase 2)WithdrawnNCT02705339What this trial is testingRociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC)Who this might be right forCarcinoma, Non-Small-Cell LungNon-Small Cell Lung CancerNonsmall Cell Lung Cancer Washington University School of Medicine
Testing effectiveness (Phase 2)UnknownNCT06334757What this trial is testingSerplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment FailureWho this might be right forNon-Squamous Non-Small Cell Lung Cancer Henan Cancer Hospital 46
Testing effectiveness (Phase 2)Active Not RecruitingNCT03433469What this trial is testingOsimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before SurgeryWho this might be right forStage I Non-Small Cell Lung CancerStage IA Non-Small Cell Lung CancerStage IB Non-Small Cell Lung Cancer+4 more University of California, San Francisco 27
Testing effectiveness (Phase 2)UnknownNCT06339242What this trial is testingFurmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal MetastasisWho this might be right forNSCLC Jiangsu Province Nanjing Brain Hospital 30
Testing effectiveness (Phase 2)Looking for participantsNCT05334277What this trial is testingFurmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNAWho this might be right forNon-small Cell Lung Cancer Sun Yat-sen University 280
Not applicableNo Longer AvailableNCT02547675What this trial is testingRociletinib (CO-1686) USA Expanded Access ProgramWho this might be right forNon-small Cell Lung Cancer Clovis Oncology, Inc.
Testing effectiveness (Phase 2)UnknownNCT04643847What this trial is testingA Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain MetastasesWho this might be right forEGFR Positive Non-small Cell Lung CancerBrain Metastases First People's Hospital of Hangzhou 47
Testing effectiveness (Phase 2)Looking for participantsNCT05394831What this trial is testingEvaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLCWho this might be right forEGFR Mutant Advanced Non-small Cell Lung Cancer J Ints Bio 150
Not applicableLooking for participantsNCT05257967What this trial is testingCSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal DiseaseWho this might be right forEGFR Activating MutationLeptomeningeal MetastasisNon Small Cell Lung Cancer British Columbia Cancer Agency 10
Testing effectiveness (Phase 2)UnknownNCT04636593What this trial is testingTrial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLCWho this might be right forNon Small Cell Lung CancerStage III NSCLCEGFR Activating Mutation First People's Hospital of Hangzhou 43
Large-scale testing (Phase 3)WithdrawnNCT06093503What this trial is testingStudy of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met ProteinWho this might be right forNon-Small Cell Lung Cancer AbbVie
Early research (Phase 1)Looking for participantsNCT04762199What this trial is testingMRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung CancerWho this might be right forAdvanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8+2 more Emory University 69
Early research (Phase 1)UnknownNCT05489731What this trial is testingVIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung CancerWho this might be right forAdvanced Non-small Cell Lung Cancer Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd. 72
Not applicableEnded earlyNCT02431169What this trial is testingGenomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease ProgressionWho this might be right forCarcinoma, Non-Small-Cell-LungNon-Small Cell Lung CancerNonsmall Cell Lung Cancer Washington University School of Medicine 5